Savient Pharmaceuticals Jumps On FDA's Approval Of Its Gout Drug

Shares of Savient Pharmaceuticals Inc SVNT surged in pre-market trading after the approval of its gout drug by the Food and Drug Administration (FDA). SVNT's shares surged 23.31% to $18.20 in pre-market trading. The FDA has approved SVNT's gout drug for adults who were not getting any results from conventional therapy. Savient Pharmaceuticals' shares have gained 2.79% over the past month and have risen 8.45% so far this year. Read more from Benzinga's Company news. The $2.5 Million Market-Beating Secret is Available. Get it here for free.